Research programme: allogenic TCR-NK cell therapies- Zelluna immunotherapy
Alternative Names: allogenic TCR NK cell therapiesLatest Information Update: 03 Mar 2023
Price :
$50 *
At a glance
- Originator Zelluna Immunotherapy
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 30 Jan 2023 Early research in Solid tumours in Norway (Parenteral) (Zelluna Immunotherapy pipeline, January 2023)